Ozempic et al. have made the last year a particularly torrid and uncertain time for sleep apnoea company RMD. In simple terms, if these new wonder drugs lead to fewer people carrying weight, it will theoretically reduce the demand for RMD products. After bouncing over 40% from its panic 2023 low, we are contemplating trimming our 5% holding from purely a volatility perspective.
- We can see RMD trading above $30 in the coming weeks. MM is long RMD in our Active Growth Portfolio.